Azienda di Servizi alla Persona
Pavia, 27100, Italy
NCT Number: NCT04919850
In animals it has been demonstrated that Saccharomyces boulardii decrease low-grade inflammation and fat mass; also Superoxide Dismutase (SOD) decrease low-grade inflammation. Therefore, the aim of this double-blind, placebo-controlled clinical trial was to assess the effect of a 60-days S. boulardii and SOD supplementation on circulating markers of inflammation, body composition, hunger sensation, pro/antioxidant ratio, hormonal, lipid profile, glucose, insulin and HOMA-IR, in obese adults (BMI 30-35 kg/m2).
Looking for future studies?
Notify Me30 year–65 year
All sexes
Interventional
Not applicable
Pavia, 27100, Italy
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes
A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
Time frame: Changes from baseline biochemical parameters for hunger sensation and hormonal status at 8 weeks
Ghrelin (pg/mL), Adiponectin (pg/ml), Peptide YY (pg/ml)
Time frame: Changes from baseline biochemical parameters for hunger sensation and hormonal status at 8 weeks
Leptin (ng/cL)
Time frame: Changes from baseline biochemical parameters for hunger sensation and hormonal status at 8 weeks
glucagon-like peptide - 1 (pmol/L)
Time frame: Changes from baseline biochemical parameters for glico-metabolic status at 8 weeks
Total cholesterol (mg/dL), Low Density Lipoprotein cholesterol (mg/dL), HDL cholesterol (mg/dL), Triglycerides (mg/dL), Apolipoprotein A (mg/dL), Apolipoprotein B (mg/dL), Glycemia (mg/dL), Uric acid (mg/dL)
Time frame: Changes from baseline biochemical parameters for glico-metabolic status at 8 weeks
Insulin (mcU/mL)
Time frame: Changes from baseline biochemical parameters for glico-metabolic status at 8 weeks
Total Proteins (g/dL), Albumin (g/dL)
Time frame: Changes from baseline biochemical parameters for glico-metabolic status at 8 weeks
HOMA index (pt)
Time frame: Changes from baseline state of hunger, fullness, desire to eat, satiety and prospective food consumption at 8 weeks
Eating motivation Visual Analogue Scale (pt): a scale from 0 to 10 points. The scale of hunger (question: "how hungry are you?") ranged from the answer "not at all" to "as hungry as I have ever felt"; the scale of fullness (question: "how full are you?") ranged from the answer "not at all" to "as full as I ever felt"; the scale of satiety (question: "how satiated are you?") ranged from "not at all" to "extremely"; the scale of desire (question: "how strong is your desire to eat?") ranged from "very weak" to "very strong"; the scale of prospective consumption (question: "how much do you think you could (or would want to) eat right now) ranged from "nothing at all" to "a very large amount"
Time frame: Changes from baseline biochemical parameters for nutritional status at 8 weeks
Iron (µg/dL)
Time frame: Changes from baseline biochemical parameters for hormonal status at 8 weeks
Thyroid Stimulating Hormone (µU/dL)
Time frame: Changes from baseline biochemical parameters for inflammation and cardiovascular risk at 8 weeks
C-Reactive Protein (mg/dL)
Time frame: Changes from baseline biochemical parameters for inflammation and cardiovascular risk at 8 weeks
Tumor Necrosis Factor-α (pg/mL), Inter Leukin-1β (pg/mL), Inter Leukin-6 (pg/mL)
Time frame: Changes from baseline biochemical parameters for inflammation and cardiovascular risk at 8 weeks
Trimethylamine (µM), Trimethylamine-N-oxide (µM)
Time frame: Changes from baseline biochemical parameters for safety at 8 weeks
Aspartate amino transferase (U/L), Alanine amino transferase (U/L), Gamma Glutamyl Transferase (U/L)
Time frame: Changes from baseline biochemical parameters for safety at 8 weeks
Creatinine (mg/dl)
Time frame: Changes from baseline anthropometric measures at 8 weeks
Height (cm), waist circumference (cm)
Time frame: Changes from baseline anthropometric measures at 8 weeks
Weight (Kg)
Time frame: Changes from baseline anthropometric measures at 8 weeks
Body mass index (kg/m2)
Time frame: Changes from baseline body composition at 8 weeks
Free Fat Mass (kg), Fat Mass (kg)
Time frame: Changes from baseline body composition at 8 weeks
Android fat (%), Gynoid fat (%)
Time frame: Changes from baseline body composition at 8 weeks
Visceral Adipose Tissue (g)
Time frame: Changes from baseline mood assessment at 8 weeks
Beck questionnaire (pt). The questionnaire is divided into 21 items which have a score from 0 to 3. A total score > 17 indicates borderline depression; > 21 moderate depression; > 31 severe depression; > 40 extreme depression.
Time frame: Changes from baseline assessment of food preferences at 8 weeks
Food Frequency Questionnaire (pt). Participants must indicate the consumption of 18 common food items, choosing one between "yes" or "no, never". Participants were also asked to estimate their usual rate of consumption, choosing from seven categories of frequency, ranging from ''never'' or ''less than once a week'' to ''seven times per week". The only exception was constituted by the item "coffee consumption", which is reported as "cups/day".
Azienda di Servizi alla Persona di Pavia
Other
Effect of 60-days Saccharomyces Boulardii and Superoxide Dismutase Supplementation on Body Composition, Hunger Sensation, Pro/Antioxidant Ratio, Inflammation and Hormonal Lipo-metabolic Biomarkers in Obese Adults: a Double-blind, Placebo-controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05742165
Behavior, Body Weight
New York, United States
View Trial DetailsNCT05882045
Body Weight, Cardiovascular Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT00342732
Body Weight, Nutrition Disorders
Phoenix, Arizona, United States
View Trial Details